drugset / Trial / NCT02257424
Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma.
Timeline
- Start
- 2014-10
- Primary completion
- 2021-10
- Completion
- 2021-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 150 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 600 mg | Oral |
| Subject | Trametinib | Small molecule | 2 mg | Oral |